All In Biotech

Drug Trial Radar · NCT06530797

A Multicenter Real-World Cohort Study of Adebrelimab Injection in the Treatment of Extensive-Stage Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jul 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

2,000

Planned (sponsor's estimate)

Start

Aug 1, 2024

Primary completion

Sep 1, 2026

Study completion Sep 1, 2026

Sponsor

Lead sponsor
Shanghai Pulmonary Hospital, Shanghai, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 31, 2024

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

The purpose of this observational study is to evaluate the safety and efficacy of Adebrelimab Injection in extensive-stage small cell lung cancer (ES-SCLC) under real-world conditions. Specifically, the study aims to assess the treatment of Adebrelimab Injection across various subgroups of ES-SCLC patients. The goal is to provide information on treatment patterns and effectiveness in real-life settings, explore potential predictive or prognostic biomarkers, and preliminarily evaluate the pharmacoeconomic indicators of Adebrelimab Injection treatment for extensive-stage small cell lung cancer.

Conditions

  • Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Interventions

  • First-line Adebrelimab regiment for advanced stage ES-SCLCDrug

    First-line Adebrelimab in any regiment for advanced stage ES-SCLC

  • Second-line and beyond Adebrelimab regiment for advanced stage ES-SCLCDrug

    Second-line and beyond Adebrelimab in any regiment for advanced stage ES-SCLC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety (The occurrence of ≥3 grade AEs)Time frame: From August 2024, patients will be followed up for 90 days after the last use of Adebrelimab

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.